Our Mission: Reduce Clinical Uncertainty

Low accuracy in liquid biopsies (i.e. low sensitivity, specificity) produces high false results (false positive, false negative). Current guidelines require imaging (mammograms, LD-CAT, etc.) but still have high false results leading to worry, confusion, unnecessary invasive procedures and wasteful expense. 

There is also a severe shortage of imaging equipment to support the increasing number of people requiring screening. Medical journals, government, and patients have all expressed concern that current solutions don't meet society's needs. And a lack of equity in access to expensive imaging and liquid biopsy technology only magnifies the problems in early cancer detection.

Unlike many other technologies that rely on difficult to find and expensive DNA processing, Definitive Diagnostics measures specific cancer-related proteins that are easily detected, cost-effective, and are the body's first indication of cancer. 

Most liquid biopsies rely on broad detection and the "likelihood" of possibly a number of cancers that require more testing. We believe in high accuracy for the most prevalent and aggressive cancers.  

Our proprietary technology delivers accurate detection of breast, lung, colorectal, ovarian and pancreatic cancers. 

We measure protein and immune biomarkers and have discovered unique biomarker patterns for individual cancers. 

These patterns do not overlap and as a result, we can determine with accuracy, which type of cancer is present (when present), and can rule out cancer from mammograms or LD-CATs that generate false results. 

The platform measures 18 biomarker parameters present in blood to accurately detect cancer with high precision.  Independant assessment of early lab results show 99% sensitivity (including Stage I detection), 97-99% specificity, and 98% Tissue of Origin.